{"success":true,"data":{"pressRelease":{"id":"170786","rtpr_id":"nACSpbzPYa-20261015","ticker":"AIMV","exchange":"OTC","all_tickers":["AIMV"],"title":"AI Maverick Intel Signs Definitive Agreement to Acquire Heal Access, an Agentic AI Healthcare Platform","author":"ACCESSWIRE","published_at":"2026-10-15T17:00:03.007Z","article_body":"NEW YORK CITY, NY / ACCESS Newswire (https://www.accessnewswire.com/) /\nOctober 15, 2026 / AI Maverick Intel, Inc. (OTCID:AIMV) (\"AIMV\" or the\n\"Company\") has entered into a definitive share purchase agreement (the \"Share\nPurchase Agreement\") to acquire, through a wholly owned subsidiary, all of the\nissued and outstanding shares of Heal Access Canada Inc. (\"Heal Access\") from\nHEAL Group Holdings Inc. (\"HEAL Group\"), AIMV's controlling stockholder. The\nShare Purchase Agreement follows the non-binding letter of intent announced on\nMarch 30, 2026. Closing is subject to a number of conditions, including AIMV\ncompleting a financing, as described below.\n\nMarket Opportunity\n\nHealthcare systems worldwide remain fragmented. Patient data sits in separate\nelectronic health records, wearables and applications, while clinicians face a\ngrowing administrative burden and the World Health Organization projects a\nglobal shortfall of 10 million health workers by 2030.\n\nIn a 2025 Digital Health Market, analysts forecast that the digital health\nmarket will reach US$574 billion by 2030, and regulatory developments such as\nthe EU AI Act are pushing health systems toward compliant, audit-ready AI\nplatforms. Heal Access is designed to serve this market as an intelligence\nlayer above the clinical systems providers already use.\n\nThe Heal Access Platform\n\nHeal Access operates an agentic AI healthcare intelligence platform that\nbrings fragmented health information together into a single intelligence layer\nconnecting patients, clinicians and healthcare organizations. The platform is\nlive in production in the United States, Canada, the United Kingdom, Germany\nand Australia.\n\nAt the core of the platform is HEALix, Heal Access's agentic AI engine. HEALix\nbrings six capabilities together in one platform: an AI Knowledge Base, AI\nHealth Companion, Intelligent Case Management, AI Patient Records, AI-powered\nassessments and triage routing, and Reporting & Analytics. Built on an\nAPI-first architecture, Heal Access integrates with existing electronic health\nrecord systems and other healthcare technologies, so organizations can add AI\ncapabilities without replacing their existing infrastructure. Responsible AI\nprinciples are built into the platform. HEALix educates rather than diagnoses,\nrecommends rather than decides, and provides explainable, compliance-aware\nguidance. The platform is designed to support HIPAA, PIPEDA and GDPR\nrequirements, and EU medical device and NHS DTAC assessments are in progress.\nHeal Access earns revenue through a hybrid software-as-a-service model that\ncombines recurring clinic and patient subscription fees, configuration and\nonboarding services, multi-year enterprise agreements and additional platform\nmodules.\n\nManagement Commentary\n\n\"When we started down this road, we wanted a real operating business in\nhealthcare AI, and that is exactly what Heal Access gives us,\" said Wayne\nCockburn, Chief Executive Officer of AIMV. \"It is live in five countries, it\nhas enterprise customers and more than 118,000 patients are already using it.\nJust as important, Heal Access has signed a non-binding letter of intent for a\nfive-year engagement with one of the largest private healthcare providers in\nthe United Kingdom. After closing, our focus is simple. We will back the Heal\nAccess team in the markets where it is already winning, push for broader\nenterprise adoption and look for opportunities that fit alongside it,\nincluding within the HEAL Group portfolio. We are also taking the steps to\nbecome a fully reporting public company, which we see as the foundation for\nAIMV's next stage of growth.\"\n\nTransaction Structure and Consideration\n\nUnder the Share Purchase Agreement, the purchase price for the Heal Access\nshares consists of US$5,000,000, subject to a customary adjustment, plus\n20,000,000 exchangeable shares of the Purchaser (the \"Exchangeable Shares\").\nEach Exchangeable Share will be exchangeable, at the holder's option, for one\nshare of AIMV common stock, and AIMV will reserve 20,000,000 shares for that\npurpose. The cash component will be satisfied at closing by the issuance to\nHEAL Group of a secured promissory note of the Purchaser (the \"Vendor Note\")\nwith the following principal terms:\n* Principal amount of US$5,000,000, as adjusted for closing working capital,\ncash and debt\n* Simple interest at 10% per annum, payable with principal at maturity\n* Two-year term from the closing date, prepayable at any time without penalty\n* Secured by a pledge of the Heal Access shares, a guarantee and security from\nHeal Access and its subsidiaries, and a guarantee by AIMV\nClosing Conditions and Timing\n\nClosing is conditional on AIMV raising, or obtaining binding commitments for,\nat least US$6 million in financing. It is also subject to the approval of the\nSpecial Committee not having been withdrawn or modified, completion of the\nexchangeable share structure, and other customary conditions, including the\nabsence of any material adverse change and any filing required under the\nInvestment Canada Act.\n\nAIMV has agreed to use commercially reasonable efforts to complete the\nfinancing on or before December 31, 2026. Either party may terminate the Share\nPurchase Agreement if closing has not occurred by February 28, 2027. There can\nbe no assurance that the financing will be completed or that the acquisition\nwill close.\n\nThis news release does not constitute an offer to sell or a solicitation of an\noffer to buy any securities.\n\nCorrection of Prior Disclosure\n\nAIMV's news release dated September 21, 2026 stated that AIMV had entered into\na definitive agreement to acquire Heal Access. That statement was incorrect.\nAt that time, the parties had entered into only the non-binding letter of\nintent announced on March 30, 2026, and the definitive Share Purchase\nAgreement described in this release was signed on October 12, 2026. AIMV\nregrets the error.\n\nRelated Party Disclosure\n\nHEAL Group is AIMV's controlling stockholder. It holds 100,000,000 shares of\nAIMV common stock, or approximately 77.0% of the 129,786,748 shares\noutstanding, all issued under a right of first refusal agreement dated\nFebruary 11, 2026. AIMV announced the issuance of 76,500,000 of these shares\non May 12, 2026. The remaining 23,500,000 shares were issued under the same\nagreement on May 26, 2026, and their issuance is being disclosed in this\nrelease. The acquisition does not trigger any further share issuances under\nthat agreement, and the 20 million exchangeable shares are the only shares\nHEAL Group will receive in the transaction. If all of the exchangeable shares\nare exchanged, HEAL Group would hold approximately 80.1% of AIMV's outstanding\ncommon stock, before any shares issued in the financing.\n\nIn addition to the US$5 million Vendor Note, Heal Access and its subsidiaries\nowe HEAL Group and its affiliates approximately US$6.4 million, which will be\nassumed by the Company at the time of Closing.\n\nThe Share Purchase Agreement was approved by the AIMV Board of Directors.\nBecause HEAL Group is AIMV's controlling stockholder, the agreement will also\nbe submitted for ratification to a special committee of directors who are\nindependent of HEAL Group, and closing is conditional on that ratification.\n\nAbout Heal Access\n\nHeal Access (Heal Access Canada Inc.) is an Alberta corporation with operating\nsubsidiaries in the United States and the United Kingdom. It operates an\nagentic AI healthcare intelligence platform that connects fragmented health\ninformation to support patients, clinicians and healthcare organizations\nacross provider networks, specialist clinics, pharmacy programs, employer\nhealth programs and population-health initiatives.\n\nAbout HEAL Group Holdings\n\nHEAL Group Holdings Inc. is a privately held health and wellness company and\nthe controlling stockholder of AIMV. Since its first acquisition in 2022, HEAL\nGroup has invested approximately US$75 million of its own capital to build a\nportfolio of 27 companies across Canada, the United States and Europe. Its\nbusinesses include mental health clinics, virtual care, chronic pain\nmanagement, licensed pharmaceutical distribution in Europe, healthcare\nproducts and devices, and revenue cycle management for U.S. healthcare\nproviders. HEAL Group's strategy centers on connecting patients, pharmacists\nand practitioners, and it is bringing its businesses together on a shared\nAI-enabled data platform, with Heal Access serving as the intelligence layer\nacross the group. Under a right of first refusal agreement entered into in\nFebruary 2026, AIMV has the first opportunity to acquire certain assets that\nHEAL Group owns. The acquisition of Heal Access is the first transaction under\nthat agreement.\n\nAbout AI Maverick Intel, Inc.\n\nAI Maverick Intel, Inc. is a Delaware corporation focused on artificial\nintelligence in healthcare. AIMV has agreed to acquire Heal Access, an agentic\nAI healthcare platform live in five countries, and intends to grow through\nHeal Access and through further acquisitions of AI and technology-enabled\nhealthcare businesses, including opportunities available to it under its right\nof first refusal agreement with HEAL Group Holdings Inc., its controlling\nstockholder. AIMV's common stock is quoted on the OTCID Basic Market operated\nby OTC Markets Group Inc. under the symbol \"AIMV\".\n\nFor further information, contact:\n\nWayne Cockburn, Chief Executive Officer, AI Maverick Intel, Inc.\nPhone: (905) 505-0770\nE-mail: aimaverickintel@gmail.com\n\nForward-Looking Statements\n\nThis news release contains forward-looking statements, which can often be\nidentified by words such as \"expects,\" \"intends,\" \"plans,\" \"will\" and similar\nexpressions. They include statements about completing the acquisition and the\nrelated financing, satisfying the closing conditions, the repayment of Heal\nAccess's liabilities to HEAL Group, Heal Access's customer relationships,\nletters of intent and growth prospects, the market opportunity for the\nplatform, potential future transactions, and AIMV's plans to become an SEC\nreporting company.\n\nThese statements reflect AIMV's current expectations and are subject to risks\nthat could cause actual results to differ materially. These include:\n* the risk that AIMV cannot complete the required financing on acceptable\nterms or at all, that the special committee does not ratify the Share Purchase\nAgreement, or that other closing conditions are not met in time;\n* Heal Access's dependence on a small number of customers, several of which\nare HEAL Group affiliates;\n* the risk that letters of intent and pipeline opportunities do not become\ndefinitive agreements or revenue;\n* Heal Access's history of operating losses and need for additional capital;\n* changing regulatory, privacy, AI and medical device requirements in the\njurisdictions where Heal Access operates;\n* delays in completing AIMV's audited financial statements or registration\nstatement;\n* AIMV's ability to become an SEC reporting company and meet the requirements\nof any trading market;\n* restrictions on the resale of the securities to be issued;\n* the conflicts of interest inherent in a transaction with AIMV's controlling\nstockholder.\nOperating metrics in this release are unaudited. Information about Heal Access\nwas provided by Heal Access and HEAL Group, and market data was obtained from\nthird-party sources. AIMV has not independently verified this information.\nReaders should not place undue reliance on forward-looking statements, which\nspeak only as of the date of this release. AIMV undertakes no obligation to\nupdate them except as required by law.\n\nSOURCE: AI Maverick Intel, Inc.\nView the original press release\n(https://www.accessnewswire.com/newsroom/en/biotechnology/ai-maverick-intel-signs-definitive-agreement-to-acquire-heal-access-an-agentic-ai-hea-1237053)\non ACCESS Newswire\n\n\nCopyright 2026 ACCESS Newswire. All Rights Reserved.","article_body_html":"","raw_payload":{"data":{"id":"nACSpbzPYa-20261015","title":"AI Maverick Intel Signs Definitive Agreement to Acquire Heal Access, an Agentic AI Healthcare Platform","author":"ACCESSWIRE","ticker":"AIMV","created":"2026-10-15T17:00:03.007Z","tickers":["AIMV"],"exchange":"OTC","article_body":"NEW YORK CITY, NY / ACCESS Newswire (https://www.accessnewswire.com/) /\nOctober 15, 2026 / AI Maverick Intel, Inc. (OTCID:AIMV) (\"AIMV\" or the\n\"Company\") has entered into a definitive share purchase agreement (the \"Share\nPurchase Agreement\") to acquire, through a wholly owned subsidiary, all of the\nissued and outstanding shares of Heal Access Canada Inc. (\"Heal Access\") from\nHEAL Group Holdings Inc. (\"HEAL Group\"), AIMV's controlling stockholder. The\nShare Purchase Agreement follows the non-binding letter of intent announced on\nMarch 30, 2026. Closing is subject to a number of conditions, including AIMV\ncompleting a financing, as described below.\n\nMarket Opportunity\n\nHealthcare systems worldwide remain fragmented. Patient data sits in separate\nelectronic health records, wearables and applications, while clinicians face a\ngrowing administrative burden and the World Health Organization projects a\nglobal shortfall of 10 million health workers by 2030.\n\nIn a 2025 Digital Health Market, analysts forecast that the digital health\nmarket will reach US$574 billion by 2030, and regulatory developments such as\nthe EU AI Act are pushing health systems toward compliant, audit-ready AI\nplatforms. Heal Access is designed to serve this market as an intelligence\nlayer above the clinical systems providers already use.\n\nThe Heal Access Platform\n\nHeal Access operates an agentic AI healthcare intelligence platform that\nbrings fragmented health information together into a single intelligence layer\nconnecting patients, clinicians and healthcare organizations. The platform is\nlive in production in the United States, Canada, the United Kingdom, Germany\nand Australia.\n\nAt the core of the platform is HEALix, Heal Access's agentic AI engine. HEALix\nbrings six capabilities together in one platform: an AI Knowledge Base, AI\nHealth Companion, Intelligent Case Management, AI Patient Records, AI-powered\nassessments and triage routing, and Reporting & Analytics. Built on an\nAPI-first architecture, Heal Access integrates with existing electronic health\nrecord systems and other healthcare technologies, so organizations can add AI\ncapabilities without replacing their existing infrastructure. Responsible AI\nprinciples are built into the platform. HEALix educates rather than diagnoses,\nrecommends rather than decides, and provides explainable, compliance-aware\nguidance. The platform is designed to support HIPAA, PIPEDA and GDPR\nrequirements, and EU medical device and NHS DTAC assessments are in progress.\nHeal Access earns revenue through a hybrid software-as-a-service model that\ncombines recurring clinic and patient subscription fees, configuration and\nonboarding services, multi-year enterprise agreements and additional platform\nmodules.\n\nManagement Commentary\n\n\"When we started down this road, we wanted a real operating business in\nhealthcare AI, and that is exactly what Heal Access gives us,\" said Wayne\nCockburn, Chief Executive Officer of AIMV. \"It is live in five countries, it\nhas enterprise customers and more than 118,000 patients are already using it.\nJust as important, Heal Access has signed a non-binding letter of intent for a\nfive-year engagement with one of the largest private healthcare providers in\nthe United Kingdom. After closing, our focus is simple. We will back the Heal\nAccess team in the markets where it is already winning, push for broader\nenterprise adoption and look for opportunities that fit alongside it,\nincluding within the HEAL Group portfolio. We are also taking the steps to\nbecome a fully reporting public company, which we see as the foundation for\nAIMV's next stage of growth.\"\n\nTransaction Structure and Consideration\n\nUnder the Share Purchase Agreement, the purchase price for the Heal Access\nshares consists of US$5,000,000, subject to a customary adjustment, plus\n20,000,000 exchangeable shares of the Purchaser (the \"Exchangeable Shares\").\nEach Exchangeable Share will be exchangeable, at the holder's option, for one\nshare of AIMV common stock, and AIMV will reserve 20,000,000 shares for that\npurpose. The cash component will be satisfied at closing by the issuance to\nHEAL Group of a secured promissory note of the Purchaser (the \"Vendor Note\")\nwith the following principal terms:\n* Principal amount of US$5,000,000, as adjusted for closing working capital,\ncash and debt\n* Simple interest at 10% per annum, payable with principal at maturity\n* Two-year term from the closing date, prepayable at any time without penalty\n* Secured by a pledge of the Heal Access shares, a guarantee and security from\nHeal Access and its subsidiaries, and a guarantee by AIMV\nClosing Conditions and Timing\n\nClosing is conditional on AIMV raising, or obtaining binding commitments for,\nat least US$6 million in financing. It is also subject to the approval of the\nSpecial Committee not having been withdrawn or modified, completion of the\nexchangeable share structure, and other customary conditions, including the\nabsence of any material adverse change and any filing required under the\nInvestment Canada Act.\n\nAIMV has agreed to use commercially reasonable efforts to complete the\nfinancing on or before December 31, 2026. Either party may terminate the Share\nPurchase Agreement if closing has not occurred by February 28, 2027. There can\nbe no assurance that the financing will be completed or that the acquisition\nwill close.\n\nThis news release does not constitute an offer to sell or a solicitation of an\noffer to buy any securities.\n\nCorrection of Prior Disclosure\n\nAIMV's news release dated September 21, 2026 stated that AIMV had entered into\na definitive agreement to acquire Heal Access. That statement was incorrect.\nAt that time, the parties had entered into only the non-binding letter of\nintent announced on March 30, 2026, and the definitive Share Purchase\nAgreement described in this release was signed on October 12, 2026. AIMV\nregrets the error.\n\nRelated Party Disclosure\n\nHEAL Group is AIMV's controlling stockholder. It holds 100,000,000 shares of\nAIMV common stock, or approximately 77.0% of the 129,786,748 shares\noutstanding, all issued under a right of first refusal agreement dated\nFebruary 11, 2026. AIMV announced the issuance of 76,500,000 of these shares\non May 12, 2026. The remaining 23,500,000 shares were issued under the same\nagreement on May 26, 2026, and their issuance is being disclosed in this\nrelease. The acquisition does not trigger any further share issuances under\nthat agreement, and the 20 million exchangeable shares are the only shares\nHEAL Group will receive in the transaction. If all of the exchangeable shares\nare exchanged, HEAL Group would hold approximately 80.1% of AIMV's outstanding\ncommon stock, before any shares issued in the financing.\n\nIn addition to the US$5 million Vendor Note, Heal Access and its subsidiaries\nowe HEAL Group and its affiliates approximately US$6.4 million, which will be\nassumed by the Company at the time of Closing.\n\nThe Share Purchase Agreement was approved by the AIMV Board of Directors.\nBecause HEAL Group is AIMV's controlling stockholder, the agreement will also\nbe submitted for ratification to a special committee of directors who are\nindependent of HEAL Group, and closing is conditional on that ratification.\n\nAbout Heal Access\n\nHeal Access (Heal Access Canada Inc.) is an Alberta corporation with operating\nsubsidiaries in the United States and the United Kingdom. It operates an\nagentic AI healthcare intelligence platform that connects fragmented health\ninformation to support patients, clinicians and healthcare organizations\nacross provider networks, specialist clinics, pharmacy programs, employer\nhealth programs and population-health initiatives.\n\nAbout HEAL Group Holdings\n\nHEAL Group Holdings Inc. is a privately held health and wellness company and\nthe controlling stockholder of AIMV. Since its first acquisition in 2022, HEAL\nGroup has invested approximately US$75 million of its own capital to build a\nportfolio of 27 companies across Canada, the United States and Europe. Its\nbusinesses include mental health clinics, virtual care, chronic pain\nmanagement, licensed pharmaceutical distribution in Europe, healthcare\nproducts and devices, and revenue cycle management for U.S. healthcare\nproviders. HEAL Group's strategy centers on connecting patients, pharmacists\nand practitioners, and it is bringing its businesses together on a shared\nAI-enabled data platform, with Heal Access serving as the intelligence layer\nacross the group. Under a right of first refusal agreement entered into in\nFebruary 2026, AIMV has the first opportunity to acquire certain assets that\nHEAL Group owns. The acquisition of Heal Access is the first transaction under\nthat agreement.\n\nAbout AI Maverick Intel, Inc.\n\nAI Maverick Intel, Inc. is a Delaware corporation focused on artificial\nintelligence in healthcare. AIMV has agreed to acquire Heal Access, an agentic\nAI healthcare platform live in five countries, and intends to grow through\nHeal Access and through further acquisitions of AI and technology-enabled\nhealthcare businesses, including opportunities available to it under its right\nof first refusal agreement with HEAL Group Holdings Inc., its controlling\nstockholder. AIMV's common stock is quoted on the OTCID Basic Market operated\nby OTC Markets Group Inc. under the symbol \"AIMV\".\n\nFor further information, contact:\n\nWayne Cockburn, Chief Executive Officer, AI Maverick Intel, Inc.\nPhone: (905) 505-0770\nE-mail: aimaverickintel@gmail.com\n\nForward-Looking Statements\n\nThis news release contains forward-looking statements, which can often be\nidentified by words such as \"expects,\" \"intends,\" \"plans,\" \"will\" and similar\nexpressions. They include statements about completing the acquisition and the\nrelated financing, satisfying the closing conditions, the repayment of Heal\nAccess's liabilities to HEAL Group, Heal Access's customer relationships,\nletters of intent and growth prospects, the market opportunity for the\nplatform, potential future transactions, and AIMV's plans to become an SEC\nreporting company.\n\nThese statements reflect AIMV's current expectations and are subject to risks\nthat could cause actual results to differ materially. These include:\n* the risk that AIMV cannot complete the required financing on acceptable\nterms or at all, that the special committee does not ratify the Share Purchase\nAgreement, or that other closing conditions are not met in time;\n* Heal Access's dependence on a small number of customers, several of which\nare HEAL Group affiliates;\n* the risk that letters of intent and pipeline opportunities do not become\ndefinitive agreements or revenue;\n* Heal Access's history of operating losses and need for additional capital;\n* changing regulatory, privacy, AI and medical device requirements in the\njurisdictions where Heal Access operates;\n* delays in completing AIMV's audited financial statements or registration\nstatement;\n* AIMV's ability to become an SEC reporting company and meet the requirements\nof any trading market;\n* restrictions on the resale of the securities to be issued;\n* the conflicts of interest inherent in a transaction with AIMV's controlling\nstockholder.\nOperating metrics in this release are unaudited. Information about Heal Access\nwas provided by Heal Access and HEAL Group, and market data was obtained from\nthird-party sources. AIMV has not independently verified this information.\nReaders should not place undue reliance on forward-looking statements, which\nspeak only as of the date of this release. AIMV undertakes no obligation to\nupdate them except as required by law.\n\nSOURCE: AI Maverick Intel, Inc.\nView the original press release\n(https://www.accessnewswire.com/newsroom/en/biotechnology/ai-maverick-intel-signs-definitive-agreement-to-acquire-heal-access-an-agentic-ai-hea-1237053)\non ACCESS Newswire\n\n\nCopyright 2026 ACCESS Newswire. All Rights Reserved."},"type":"article","timestamp":"2026-10-15T17:00:03.072328111Z","server_sent_at_ms":1792083603072},"received_at":"2026-10-15T17:00:03.128Z","source_url":"https://www.accessnewswire.com/newsroom/en/biotechnology/ai-maverick-intel-signs-definitive-agreement-to-acquire-heal-access-an-agentic-ai-hea-1237053"},"analysis":{"id":"158967","press_release_id":"170786","analysis_json":{"industry":{"label":"Health Care Technology","sector":"Health Care"},"redFlags":["Related-party transaction with controlling stockholder (HEAL Group, 77% owner) as seller","Closing conditioned on a still-unraised US$6 million financing; no assurance it completes","Prior release (Sept 21, 2026) incorrectly claimed a definitive agreement was signed — disclosure controls concern","Late disclosure of 23.5 million shares issued to controlling stockholder without announcement","AIMV assumes US$6.4 million of intercompany liabilities owed to HEAL Group affiliates","Heal Access has a history of operating losses, heavy customer concentration, and several customers are HEAL Group affiliates","Trading on OTCID Basic Market; further dilution from both the financing and 20M exchangeable shares","Revenue and operating metrics are unaudited and provided by the seller"],"eventType":"m_and_a","narrative":"AI Maverick Intel (OTCID: AIMV) signed a definitive share purchase agreement on October 12, 2026 to acquire Heal Access Canada, an agentic AI healthcare platform live in five countries with more than 118,000 patients using it.\n\nConsideration is US$5 million (paid via a secured two-year vendor note bearing 10% simple interest) plus 20 million exchangeable shares, each convertible into one AIMV share. Because the seller, HEAL Group, is AIMV's controlling stockholder with 77% ownership, the deal would lift its stake to roughly 80.1% and requires ratification by a special committee of independent directors.\n\nClosing is conditional on AIMV raising at least US$6 million by year-end 2026, special-committee approval, Investment Canada Act filings, and no material adverse change, with a February 28, 2027 outside termination date. AIMV will also assume approximately US$6.4 million Heal Access owes HEAL Group affiliates.\n\nThe release also corrects a prior misstatement — the September 21 release incorrectly claimed a definitive agreement was already signed — and disclosed 23.5 million shares previously issued to HEAL Group without announcement, underscoring governance and disclosure concerns around this related-party transaction.","sentiment":"mixed","agentHooks":{"shouldPost":true,"suggestedAngle":"Micro-cap OTC shell converts into a related-party healthcare-AI rollup — watch the $6M financing condition and special-committee ratification as make-or-break gates."},"keyFigures":{"dealValueUsd":5000000,"customDimensions":{"vendor_note_rate":"10% simple interest per annum","shares_outstanding":129786748,"exchangeable_shares":20000000,"financing_condition":"$6 million","vendor_note_principal":"$5,000,000","patients_using_platform":"118,000","assumed_intercompany_debt":"$6.4 million","heal_group_current_ownership":"77.0%","heal_group_pro_forma_ownership":"80.1%"}},"quotedText":"Heal Access's dependence on a small number of customers, several of which are HEAL Group affiliates","namedEntities":{"people":[{"name":"Wayne Cockburn","role":"CEO of AIMV"}],"products":["HEALix"],"companies":[{"name":"AI Maverick Intel, Inc.","ticker":"AIMV","relationship":"acquirer/filer"},{"name":"Heal Access Canada Inc.","relationship":"target"},{"name":"HEAL Group Holdings Inc.","relationship":"seller and controlling stockholder of AIMV"}],"dollarAmounts":[{"amount":"US$5,000,000","context":"cash purchase price satisfied via secured vendor note"},{"amount":"US$6 million","context":"minimum financing required as closing condition"},{"amount":"US$6.4 million","context":"Heal Access liabilities owed to HEAL Group to be assumed by AIMV"},{"amount":"US$75 million","context":"HEAL Group capital invested across its 27-company portfolio"},{"amount":"US$574 billion","context":"projected digital health market size by 2030"}]},"materialImpact":{"score":4,"reasoning":"Definitive agreement to acquire an operating business from AIMV's controlling stockholder — a transformative M&A event for a micro-cap OTC shell, funded partly by a $5M vendor note and conditioned on a $6M financing. However, the related-party nature, assumed $6.4M intercompany debt, and the need to correct a prior false disclosure add significant risk."},"tickerRelevance":{"others":[],"primary":"AIMV"},"globalImportance":22,"audienceRelevance":12,"eventTypeSecondary":["debt_offering"],"importanceComponents":{"tickerTier":"micro-cap OTC","eventGravity":"definitive M&A agreement but small dollar value","dilutionOverhang":true,"relatedPartyDeal":true}},"event_type":"m_and_a","event_type_secondary":["debt_offering"],"sentiment":"mixed","material_impact_score":4,"narrative":"AI Maverick Intel (OTCID: AIMV) signed a definitive share purchase agreement on October 12, 2026 to acquire Heal Access Canada, an agentic AI healthcare platform live in five countries with more than 118,000 patients using it.\n\nConsideration is US$5 million (paid via a secured two-year vendor note bearing 10% simple interest) plus 20 million exchangeable shares, each convertible into one AIMV share. Because the seller, HEAL Group, is AIMV's controlling stockholder with 77% ownership, the deal would lift its stake to roughly 80.1% and requires ratification by a special committee of independent directors.\n\nClosing is conditional on AIMV raising at least US$6 million by year-end 2026, special-committee approval, Investment Canada Act filings, and no material adverse change, with a February 28, 2027 outside termination date. AIMV will also assume approximately US$6.4 million Heal Access owes HEAL Group affiliates.\n\nThe release also corrects a prior misstatement — the September 21 release incorrectly claimed a definitive agreement was already signed — and disclosed 23.5 million shares previously issued to HEAL Group without announcement, underscoring governance and disclosure concerns around this related-party transaction.","key_figures":{"dealValueUsd":5000000,"customDimensions":{"vendor_note_rate":"10% simple interest per annum","shares_outstanding":129786748,"exchangeable_shares":20000000,"financing_condition":"$6 million","vendor_note_principal":"$5,000,000","patients_using_platform":"118,000","assumed_intercompany_debt":"$6.4 million","heal_group_current_ownership":"77.0%","heal_group_pro_forma_ownership":"80.1%"}},"named_entities":{"people":[{"name":"Wayne Cockburn","role":"CEO of AIMV"}],"products":["HEALix"],"companies":[{"name":"AI Maverick Intel, Inc.","ticker":"AIMV","relationship":"acquirer/filer"},{"name":"Heal Access Canada Inc.","relationship":"target"},{"name":"HEAL Group Holdings Inc.","relationship":"seller and controlling stockholder of AIMV"}],"dollarAmounts":[{"amount":"US$5,000,000","context":"cash purchase price satisfied via secured vendor note"},{"amount":"US$6 million","context":"minimum financing required as closing condition"},{"amount":"US$6.4 million","context":"Heal Access liabilities owed to HEAL Group to be assumed by AIMV"},{"amount":"US$75 million","context":"HEAL Group capital invested across its 27-company portfolio"},{"amount":"US$574 billion","context":"projected digital health market size by 2030"}]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:5c812bd9e28b810d","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-10-15T17:00:12.125Z","global_importance":22,"audience_relevance":12,"importance_components":{"tickerTier":"micro-cap OTC","eventGravity":"definitive M&A agreement but small dollar value","dilutionOverhang":true,"relatedPartyDeal":true}},"durationMs":8978,"modelName":"glm-5.3-flashx"}}